SAM
PACB icon

Soviero Asset Management’s Pacific Biosciences PACB Stock Holding History

Soviero Asset Management’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-50,000
Closed -$491K – 48
2023
Q4 		$491K Buy
+50,000
New +$409K 0.24% 33

Other funds holding PACB

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MA
Madrone Advisors Menlo Park, California $1.03B AUM 20.53% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
EDRH
Edmond de Rothschild Holding Chambesy, Switzerland $6.91B AUM 19.7% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return

Soviero Asset Management's PACB Position: Q1 2024 in Review

Soviero Asset Management sold out of Pacific Biosciences (PACB) in Q1 2024, closing a stake of 50,000 shares — an estimated $491K sold.

Soviero Asset Management first reported a position in PACB in Q4 2023 and held it in 1 quarter. The position peaked at $491K in Q4 2023. 268 funds tracked by Wall St. Rank hold PACB as of Q1 2024.

  • Soviero Asset Management reported no remaining Pacific Biosciences position as of Q1 2024 after selling out during the quarter.
  • Soviero Asset Management sold 50,000 Pacific Biosciences shares in Q1 2024, an estimated $491K.
  • Soviero Asset Management first reported a position in Pacific Biosciences in Q4 2023 and held it in 1 quarter.
  • Soviero Asset Management's Pacific Biosciences position peaked at $491K in Q4 2023.
  • 268 funds tracked by Wall St. Rank held Pacific Biosciences as of Q1 2024.

Based on Soviero Asset Management's 13F filing for Q1 2024, filed 15 May 2024.